SARS-CoV-2 Hijacks Immune Cells, Triggering Severe Lung Inflammation

SARS‑CoV‑2 can inflict severe lung damage in critically ill patients through more than just direct infection of airway cells. Recent research indicates that the virus also initiates a hyperinflammatory response in which immune cells become infected themselves. Once compromised, these cells cease to combat the virus and instead release large amounts of inflammatory mediators, amplifying lung inflammation.

This cycle of immune cell infection and dysregulated cytokine release explains why some patients develop a rapidly worsening respiratory failure despite antiviral therapies. The heightened inflammation can damage alveolar structures, impair gas exchange, and contribute to the high mortality seen in the most severe COVID‑19 cases.

Understanding this dual mechanism—direct viral cytopathic effect combined with immune‑cell‑driven hyperinflammation—may guide the development of targeted therapies aimed at preserving immune function while controlling excessive inflammatory responses in the lungs.